LBI-HTA - Publications - Search - Subject: WC Communicable diseases
Number of items at this level: 28.

Gartlehner, G. (2007): [New vaccines: Horizon scanning]. HTA-Newsletter 59: 4.

Jonas, S. and Jessner, W. and Rafetseder, O. and Wild, C. (2005): [Chronic hepatitis C in Austria]. Mitteilungen der Sanitätsverwaltung 01: 5-7.

Jonas, S. and Jessner, W. and Rafetseder, O. and Wild, C. (2004): [Chronic hepatitis C: Implications for therapy and economic resources in Austria]. ITA-Projektbericht 26.

Jonas, S. and Wild, C. and Schmetterer, L. and Sycha, T. and Frank, W. (2001): [Immunoglobulins in transplant medicine: Prevention and therapy of cytomegalovirus infections. Systematic review and meta-analysis]. ITA-Projektbericht 19.

Kisser, A. (2016): Hepatitis C virus screening in hospitals. Decision Support Document 102.

Kisser, A. and Zechmeister-Koss, I. (2013): P16/Ki-67 Dual Stain in the triage of PAPIII/IIID cytology in cervical cancer screening . HTA-Projektbericht 72.

Piso, B. and Reinsperger, I. (2015): Vaccination against human papillomavirus (HPV). Decision-aid for young women and girls. Decision Support Document 79.

Sprenger, M. (2005): [Oseltamivir (Tamiflu)]. HTA-Newsletter 43: 1-2.

Wild, C. (2006): [Antiviral treatment for chronic hepatitis C]. HTA-Newsletter 45: 4.

Wild, C. (2005): [Immunoglobulin in neonates and preterm infants]. HTA-Newsletter 41: 2-3.

Wild, C. (2005): [Recombinant activated C protein for severe sepsis]. HTA-Newsletter 38: 4.

Wild, C. (2004): [Prevention and therapy of Hepatitis C]. HTA-Newsletter 29: 3-4.

Wild, C. (2003): [Activated protein C for severe sepsis]. HTA-Newsletter 18: 2.

Wild, C. (2003): [Use of genotypic resistance testing to optimise HIV-therapy]. HTA-Newsletter 14: 3.

Wild, C. (2002): [Vaccines for preventing influenza]. HTA-Newsletter 07: 3-4.

Wild, C. (2002): [Antifungal agents in the treatment of invasive aspergillosis]. HTA-Newsletter 04: 4.

Wild, C. (2001): [Cytomegalovirus prophylaxis and therapy]. HTA-Newsletter 02: 3-4.

Wild, C. (2001): [Immunoglobulins: Effectiveness and costs]. ORF ON Science.

Wild, C. (2000): [The C-reactive protein test in the diagnosis of infections]. ITA-Newsletter September 2000: 3.

Wild, C. and Jonas, S. (2001): [Immunoglobulins in transplant medicine: Prevention and therapy of cytomegalovirus infections]. ITA-Newsletter September 2001: 9-10.

Wild, C. and Jonas, S. and Frank, W. and Schmetterer, L. and Sycha, T. (2002): [Immunoglobulins in transplant medicine. Prevention and therapy of cytomegalovirus infections: An Assessment]. Transplantationsmedizin (02): 65-73.

Wild, C. and Jonas, S. and Frank, W. and Schmetterer, L. and Sycha, T. (2001): [Immunoglobulins in transplant medicine. Prevention and therapy of cytomegalovirus infections: An Assessment]. European Surgery: Acta Chirurgica Austriaca 33 (Supplement 178).

Wild, C. and Jonas, S. and Frank, W. and Traunmüller, F. (2001): [Invasive aspergillosis: State of the art in diagnosis, treatment and conditions. An assessment]. ITA-Projektbericht 18.

Wild, C. and Piribauer, F. and Stergner, A. (2009): New influenza (swine flu) – data & facts for decision support. Decision Support Document 35.

Zechmeister, I. (2007): [Hepatitis C therapy]. HTA-Newsletter 59: 2.

Zechmeister, I. and Sroczynski, G. and Rafetseder, O. and Jonas, S. (2006): [Chronic hepatitis C: Decision analytic modeling]. ITA-Projektbericht 29.

Zechmeister-Koss, I. (2013): Zostavax® for the prevention of herpes zoster and postherpetic neuralagia. Pilot assessment using the draft HTA Core Model for Rapid Relative Effectiveness Assessment. Pilot-ID: WP-SA-1. Decision Support Document 73.

Zechmeister-Koss, I. and Reichel, M. (2012): Health status and access to health care of homeless people: A literature review. HTA-Projektbericht 63.

This list was generated on Mon Mar 27 00:00:31 2017 CEST.